
    
      Patients were divided into 3 groups:

        1. DPP-4 inhibitor treatment group (45 cases): DPP-4 inhibitor (sitagliptin phosphate)
           combined with metformin and/or acarbose;

        2. insulin treatment group (45 cases): insulin (insulin glargine or insulin detemir) and/or
           metformin;

        3. Sulfonylureas treatment group (45 cases): sulfonylureas combined with metformin and/or
           acarbose;
    
  